Core Insights - Zelluna is hosting a Capital Markets Update on April 14, 2026, to present advancements in its TCR-NK cell therapy platform and ongoing clinical activities [1][2] Company Overview - Zelluna ASA is focused on developing allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for solid cancers, with its lead candidate being ZI-MA4-1, the first MAGE-A4 targeting TCR-NK therapy [5] - The company submitted its Clinical Trial Application to the UK MHRA in December 2025, with initial clinical data expected to be available from mid-2026 [5] Event Details - The Capital Markets Update will take place at Hotel Continental in Oslo, starting with registration and lunch at 11:30, followed by presentations and Q&A from 12:00 [2][3] - Presentations will be led by Dr. Namir Hassan, CEO of Zelluna, and Professor Fiona Thistlethwaite, a Medical Oncology Consultant and lead investigator for Zelluna's ZIMA-101 study [3]

Core Insights - Zelluna has appointed Geir Christian Melen as the new Chief Financial Officer, effective January 1, 2026, succeeding Hans Vassgård Eid who will step down at the end of December 2025 [1][2][3] Company Overview - Zelluna ASA is a biotechnology company focused on developing allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for cancer treatment [4] - The company's lead program, ZI-MA4-1, targets the MAGE-A4 tumor antigen and is expected to enter clinical trials in 2026 [4] Leadership Transition - Geir Christian Melen has over seven years of experience with Zelluna as Finance Director and possesses a strong understanding of the company's TCR-NK platform and financial strategy [2][3] - The CEO of Zelluna, Namir Hassan, expressed appreciation for Hans Vassgård Eid's contributions, particularly in integrating Zelluna and Ultimovacs and preparing the company for clinical development [2]